Main Menu Jump to Page


Retainer Agreement
info@rosenlegal.com

bluebird bio shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

bluebird bio, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) resulting from allegations that bluebird bio may have issued materially misleading business information to the investing public.

If you purchased shares of bluebird bio and would like to join the action, please click "Join This Class Action," above. 


Press Release

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against bluebird bio, Inc. – BLUE

New York, N.Y., December 24, 2018. Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) resulting from allegations that bluebird bio may have issued materially misleading business information to the investing public.

On December 1, 2018, bluebird bio informed investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” Then, on December 3, 2018, an article on Seeking Alpha asserted that “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” On this news, bluebird bio’s stock price fell $6.39 per share or approximately 5.2% to close at $116.50 on December 3, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by bluebird bio, investors. If you purchased shares of bluebird bio, please visit the firm’s website at https://www.rosenlegal.com/cases-1482.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      zhalper@rosenlegal.com
      www.rosenlegal.com